Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P12829
UPID:
MYL4_HUMAN
Alternative names:
Myosin light chain 1, embryonic muscle/atrial isoform; Myosin light chain alkali GT-1 isoform
Alternative UPACC:
P12829; D3DXJ7; P11783
Background:
Myosin light chain 4, also known as Myosin light chain 1, embryonic muscle/atrial isoform or Myosin light chain alkali GT-1 isoform, plays a crucial role in muscle contraction mechanisms. It acts as a regulatory light chain of myosin and is distinguished by its inability to bind calcium, setting it apart from other myosin light chains.
Therapeutic significance:
Linked to Atrial fibrillation, familial, 18, Myosin light chain 4's genetic variants underscore its clinical importance. This connection highlights the protein's potential as a target for therapeutic interventions aimed at mitigating atrial fibrillation's risks, including stroke and heart failure.